Agenus (AGEN) vs Relmada Therapeutics (RLMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Agenus (AGEN) has outperformed Relmada Therapeutics (RLMD) over the past year, gaining 78.1% versus a gain of 63.3%. Over five years, RLMD leads with a -86.2% price change compared with -92.7% for AGEN. Agenus is the larger company by market cap ($340.5 million vs $338.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGEN | RLMD |
|---|---|---|
| Share price | $7.54 | $3.17 |
| Market cap | $340.52M | $338.14M |
| 1-day change | -0.40% | -2.46% |
| YTD return | +141.08% | -32.71% |
| 1-year return | +78.12% | +63.32% |
| 5-year return | -92.74% | -86.25% |
| P/E ratio (TTM) | 2.98 | — |
| EPS (TTM) | $2.53 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.31 | $8.00 |
| 52-week low | $2.71 | $1.80 |
| Distance from 52-week high | -26.87% | -60.38% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +249.20% | +239.12% |
| Average volume | 4.26M | 1.33M |
| Shares outstanding | 45.16M | 106.67M |
| Employees | 81 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AGEN has outperformed RLMD by 14.8 percentage points over the past year.
About Agenus
AGEN stock →Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About Relmada Therapeutics
RLMD stock →Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
AGEN vs RLMD FAQ
Which is bigger, Agenus or Relmada Therapeutics?
Agenus (AGEN) is larger, with a market capitalization of $340.52M compared with $338.14M for Relmada Therapeutics (RLMD).
Which stock has performed better over the past year, AGEN or RLMD?
AGEN returned +78.12% over the past 12 months, compared with +63.32% for RLMD (price return, excluding dividends). Past performance does not predict future results.
Are Agenus and Relmada Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Agenus and Biotechnology: Pharmaceutical Preparations for Relmada Therapeutics.